Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.42 |
| ▸ | HTR1D | P28221 | 8/20 | 0.40 |
| ▸ | HTR1B | P28222 | 7/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558261 | 0.95 | HTR1A (0.42) | HTR1AHTR1DHTR1BSLC6A4HTR7 | |
| SCHEMBL4353972 | 0.91 | HTR1A (0.43) | HTR1AHTR1DHTR1BSLC6A4HTR7 | |
| SCHEMBL4352038 | 0.90 | HTR1A (0.43) | HTR1AHTR1DHTR1BSLC6A4HTR7 | |
| SCHEMBL6362007 | 0.89 | HTR1D (0.51) | HTR1AHTR1DHTR1BSLC6A4HTR7 | |
| SCHEMBL6356507 | 0.89 | USP2 (0.43) | HTR1AHTR1DSLC6A4HTR7KCNH2 | |
| SCHEMBL4352170 | 0.88 | HTR1A (0.47) | HTR1AHTR1DSLC6A4HTR7KCNH2 | |
| Hydrochloric Acid SCHEMBL9263047 | 0.88 | HTR1D (0.50) | HTR1AHTR1DHTR1BSLC6A4HTR7 | |
| SCHEMBL4347875 | 0.85 | HTR1A (0.42) | HTR1ASLC6A4HTR7KCNH2 | |
| Hydrochloric Acid SCHEMBL4344356 | 0.84 | HTR1A (0.41) | HTR1ASLC6A4HTR7KCNH2 | |
| SCHEMBL4346029 | 0.83 | HTR1A (0.48) | HTR1AHTR1DHTR1BSLC6A4HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | claimed |
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137733-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20050095286-A1 | Extended release compositions | FABRE KRAMER PHARMACEUTICALS, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | HTR5A, TPH2, IDO2 | HTR1A 15/4885HTR1D 35/4885HTR1B 43/4885 |
| US-20050095286-A1 | Extended release compositions | PDE3A, GIPR, PDE7A | HTR1A 22/4885HTR1D 29/4885HTR1B 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.